<DOC>
	<DOCNO>NCT01111045</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy intraarticular BMP-7 treatment osteoarthritis knee .</brief_summary>
	<brief_title>Dose Finding Study Bone Morphogenetic Protein 7 ( BMP-7 ) Subjects With Osteoarthritis ( OA ) Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<criteria>Ambulatory diagnosis OA knee symptom least 6 month pain majority day last 30 day . Symptoms must include knee joint pain . A male female adult age &gt; 40 year female subject childbearing potential must negative serum pregnancy test screen negative urine pregnancy test day injection Radiographic evidence least one tibiofemoral osteophyte Osteoarthritis Research Society International ( OARSI ) Atlas joint space narrow grade 1 2 index knee WOMAC pain score &gt; 8 screen baseline Able comply study give inform consent Able read , write understand English A requirement treatment opioids pain relief . Unwilling abstain NSAIDs and/or analgesic medication 48 hour acetaminophen 24 hour prior pain assessment study . Subjects take low dose aspirin cardiovascular health may remain stable dose throughout study . Using handicap assistance device ( i.e. , cane , walker ) &gt; 50 % time . Undergoing new physical therapy participate weight loss exercise program stable least 3 month prior screen visit 1 remain stable participation study . History arthroscopic open surgery index knee past 12 month plan surgery study . History joint replacement surgery ( index knee ) . Received corticosteroid , short act hyaluronic acid , intraarticular injection index knee within 3 month screen and/or willing abstain treatment duration study Received long act hyaluronic acid injection index knee within 6 month screen and/or willing abstain treatment duration study . History past 10 year reactive arthritis , rheumatoid arthritis , psoriatic arthritis , ankylose spondylitis , arthritis associate inflammatory bowel disease , sarcoidosis , amyloidosis fibromyalgia . Clinical sign symptom active knee infection radiographic evidence crystal disease chondrocalcinosis ( i.e. , gout CPPD ) . A history abnormal laboratory result ≥2.5 x ULN indicative significant medical disease , opinion investigator , would preclude subject participation study Any following abnormal laboratory result screen : 1 . ALT AST ≥2.5x ULN 2 . Hemoglobin &lt; 11.5 g/dL ( Female ) &lt; 13.2 g/dL ( Male ) 3 . WBC &lt; 3500 cells/mm3 4 . Lymphocyte count ≤1000 cells/mm3 5 . Serum creatinine ≥1.5 x ULN 6 . Platelet count central laboratory lower limit normal . History malignancy past ten year ( &lt; 10 year ) , exception resect basal cell , squamous cell skin , resect cervical atypia carcinoma situ . Significant hip pain , ipsilateral index knee may interfere assessment index knee pain Skin breakdown knee injection would take place A know clinically suspected infection human immunodeficiency virus ( HIV ) , hepatitis C B virus Participated within 3 month participate concurrently another investigational drug vaccine study A history drug alcohol dependence abuse past 3 year Previous treatment BMP7 bone morphogenetic protein A female reproductive capability unwilling use birth control duration study and/or intend conceive within 12 month dose . Other serious , nonmalignant , significant , acute chronic medical psychiatric illness , judgment investigator , could compromise subject safety , limit subject 's ability complete study , and/or compromise objective study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>